 "Jaipur: Nearly 70 volunteers given Covaxin as part of Phase III trials")
Nearly 70 volunteers were given Covaxin, a vaccine being developed indigenously for coronavirus, in the Phase III trials here, an official said on Friday.
They were given the vaccine at a private hospital in Jaipur.
Covaxin is being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Two trials of the vaccine have been conducted and the results of the first phase were released a few days ago by the ICMR, said the principal investigator for the clinical trials, Dr Manish Jain.
He said the volunteers being given the vaccine will be constantly monitored.
The volunteers have been briefed that there may be mild fever or pain due to it.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app